Cilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin
Journal of Experimental Medicine · 07.12.2026 · 223 (12)
DOI: 10.1084/jem.20260700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 11.11.2026. Verfasst von Sara Rega und 23 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cardio-Oncology and Vascular Biology, Centro Cardiologico Monzino IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Aortic Aneurysm, Thoracic, Snake Venoms, Integrin alphaV. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Fondazione Gigi e Pupa Ferrari.
Abstract (Originalsprache)
Thoracic aortic aneurysm (TAA) is one of the major causes of morbidity and mortality worldwide, still lacking an etiologic therapy. Aberrant activation of TGF-β and dysregulation of mechanotransduction signalling in vascular smooth muscle cells (VSMCs) play a key role in the pathology. However, a precise picture of molecular mechanisms in the disease is still unclear. Integrins containing the αV subunit are central in pro-fibrotic pathways mediated by TGF-β and mechanotransduction signalling pathways, but their role as a potential therapeutic target in syndromic and sporadic TAAs still needs investigation. We showed higher expression levels of αV integrin in both types of human TAAs and that the αV integrin inhibitor Cilengitide limits pro-fibrotic events in patient-derived VSMCs. In vivo results defined Cilengitide as the most effective and promising drug for the treatment of TAAs in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Cardio-Oncology and Vascular Biology, Centro Cardiologico Monzino IRCCS, Milan, Italy.
- Animal Facility, Centro Cardiologico Monzino IRCCS, Milan, Italy.
- Cardiovascular Biology Laboratory, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
- Bioinformatics Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Humanitas Cardio Center, IRCCS Humanitas Research Hospital , Milan, Italy.
ORCID-Profile: Sara Rega, Silvia Bouhuis, Maddalena Brusati, Tea Maverna, Nadia Fanotti, Manuel Casaburo, Simone Vodret, Francesco Riccitelli, Federico Celotto, Luca Lambroia, Montserrat Climent, Leonardo Elia, Martina Vescio, Linda Pattini, Rosaria Santoro, Veronika Myasoedova, Paolo Poggio, Giorgia Bonalumi, Nathasha Samali Udugampolage, Jacopo Taurino, Alessandro Pini, Serena Zacchigna, Giulio Pompilio, Gianluca L Perrucci
Förderung
- Italian Ministry of Health
- Fondazione Gigi e Pupa Ferrari
Zitieren
APA
Rega, S., Bouhuis, S., Brusati, M., Maverna, T., Fanotti, N., Casaburo, M., Vodret, S., Riccitelli, F., Celotto, F., Lambroia, L., Climent, M., Elia, L., Vescio, M., Pattini, L., Santoro, R., Myasoedova, V., Poggio, P., Bonalumi, G., Udugampolage, N. S., …, & Perrucci, G. L. (2026). Cilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin. Journal of Experimental Medicine, 223(12). https://doi.org/10.1084/jem.20260700
Vancouver
Rega S, Bouhuis S, Brusati M, Maverna T, Fanotti N, Casaburo M, et al. Cilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin. Journal of Experimental Medicine. 2026;223(12). doi:10.1084/jem.20260700
BibTeX
@article{Rega2026,
author = {Rega, Sara and Bouhuis, Silvia and Brusati, Maddalena and Maverna, Tea and Fanotti, Nadia and Casaburo, Manuel and Vodret, Simone and Riccitelli, Francesco and Celotto, Federico and Lambroia, Luca and Climent, Montserrat and Elia, Leonardo and Vescio, Martina and Pattini, Linda and Santoro, Rosaria and Myasoedova, Veronika and Poggio, Paolo and Bonalumi, Giorgia and Udugampolage, Nathasha Samali and Taurino, Jacopo and Pini, Alessandro and Zacchigna, Serena and Pompilio, Giulio and Perrucci, Gianluca L},
title = {Cilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {12},
doi = {10.1084/jem.20260700}
}
EUVIMED